PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases

Abstract excerpt

The phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) signaling pathway has been implicated as a cancer target. Big pharma players and small companies have been developing small molecule inhibitors of PI3K and/or mTOR since the 1990s. Although four inhibitors have been approved, many open questions regarding tolerability, patient selection, sensitivity markers, development of resistances,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Tuberous Sclerosis Complex Research